Patients on MED
|
54
|
49
|
36
|
9
|
7
|
10
|
165
|
Patients on MED with ADR
|
10
|
6
|
11
|
2
|
–
|
1
|
30
|
Patients on MED with ADR(%)
|
18.5
|
12.2
|
30.5
|
22.2
|
–
|
10
|
18.2
|
Infections
|
–
|
–
|
1
|
–
|
–
|
1
|
2
|
Blood and lymphatic system disorders:
|
- Thrombocytopenia
|
–
|
–
|
1
|
–
|
–
|
–
|
1
|
Nervous system disorders:
|
- Headache/dizziness/discomfort
|
–
|
–
|
1
|
–
|
–
|
–
|
1
|
Eye disorders:
|
- Uveitis
|
2
|
1
|
–
|
–
|
–
|
–
|
3
|
Gastrointestinal disorders:
|
- Nausea/vomiting
|
2
|
3
|
1
|
–
|
–
|
–
|
6
|
- Epigastric pain
|
–
|
1
|
–
|
–
|
–
|
–
|
1
|
Hepatobiliary disorders:
|
-↑ liver enzymes
|
–
|
–
|
–
|
1
|
–
|
–
|
1
|
Skin and subcutaneous tissue disorders:
|
- Atopic dermatitis
|
1
|
–
|
–
|
–
|
–
|
–
|
1
|
- Psoriasis
|
–
|
1
|
–
|
–
|
–
|
–
|
1
|
- Urticaria
|
–
|
–
|
3
|
1
|
–
|
–
|
4
|
Renal and urinary disorders:
|
- Nephritis
|
1
|
–
|
–
|
–
|
–
|
–
|
1
|
- Hematuria
|
–
|
1
|
–
|
–
|
–
|
–
|
1
|
General disorders and administration site conditions:
|
- Anaphylaxis
|
–
|
–
|
2
|
–
|
–
|
–
|
2
|
- Local reactions and pain
|
5
|
1
|
2
|
–
|
–
|
–
|
8
|
Total number of ADRs
|
11
|
8
|
11
|
2
|
–
|
1
|
33
|